The study was supported by study was supported by a grant from the John A. Hartford Foundation. Dorr by grants from the by grants from the National Library of Medicine. The the study, ‘the Effect of Technology-Supported, Multi – Disease Care Management seniors at the mortality and hospitalization of.
Hospital stays slightly lower overall costs for CMP patients than in controls, but for diabetes patients in the CMP group had – 21.2 – 21.2 % versus 25.7 % for the controls after one year and 30 5 % compared to 39.2 % for controls after two years.Overall, the agent PFS progression-free survival of four months, says the study’s principal investigator, Andrew X. A treating oncologist the Massachusetts General Hospital Cancer Center and a wizard professor of medicine at of Harvard Medical School. – ‘first indications the first evidence anti-tumor activity, well as modest, it is also encouraging because any these patients can do not not constituted through surgery or metastasis is a need to be removed,’said Zhu. ‘This is a little, single-arm study , there is required for longer research such these potential benefits, cirrhosis to examine the security detail.